大家健康（中旬版）
大傢健康（中旬版）
대가건강（중순판）
GOOD HEALTH FOR ALL
2014年
8期
126-127,128
,共3页
培美曲塞%顺铂%食道癌%临床疗效
培美麯塞%順鉑%食道癌%臨床療效
배미곡새%순박%식도암%림상료효
pemetrexed%cisplatin%esophageal cancer%clinical effect
目的：探讨培美曲塞与顺铂联合治疗晚期食道癌的临床应用价值。方法：选择2013年1月-12月我院收治的患有晚期食道癌的病人72例，将其分成对照组与研究组，每组各36例，对照组采用5-氟尿嘧啶联合顺铂进行治疗，研究组给予培美曲塞联合顺铂，比较分析两组临床疗效。结果：经治疗，研究组的治疗总有效率为97．2％，显著高于对照组（P＜0．05）。研究组患者的恶心与呕吐、便秘、白细胞降低、贫血等不良发应的发生率均显著低于对照组（P＜0．05）。结论：将培美曲塞与顺铂联合运用于晚期食道癌的临床治疗，疗效确切，不良反应小，患者耐受性好，值得临床推广与应用。
目的：探討培美麯塞與順鉑聯閤治療晚期食道癌的臨床應用價值。方法：選擇2013年1月-12月我院收治的患有晚期食道癌的病人72例，將其分成對照組與研究組，每組各36例，對照組採用5-氟尿嘧啶聯閤順鉑進行治療，研究組給予培美麯塞聯閤順鉑，比較分析兩組臨床療效。結果：經治療，研究組的治療總有效率為97．2％，顯著高于對照組（P＜0．05）。研究組患者的噁心與嘔吐、便祕、白細胞降低、貧血等不良髮應的髮生率均顯著低于對照組（P＜0．05）。結論：將培美麯塞與順鉑聯閤運用于晚期食道癌的臨床治療，療效確切，不良反應小，患者耐受性好，值得臨床推廣與應用。
목적：탐토배미곡새여순박연합치료만기식도암적림상응용개치。방법：선택2013년1월-12월아원수치적환유만기식도암적병인72례，장기분성대조조여연구조，매조각36례，대조조채용5-불뇨밀정연합순박진행치료，연구조급여배미곡새연합순박，비교분석량조림상료효。결과：경치료，연구조적치료총유효솔위97．2％，현저고우대조조（P＜0．05）。연구조환자적악심여구토、편비、백세포강저、빈혈등불량발응적발생솔균현저저우대조조（P＜0．05）。결론：장배미곡새여순박연합운용우만기식도암적림상치료，료효학절，불량반응소，환자내수성호，치득림상추엄여응용。
Objective:To investigate the pemetrexed and cisplatin in clinical application value of combination therapy in the treatment of advanced esophageal cancer.Methods:72 cases of 2013 -12 months of January in our hospital of patients with advanced esophageal cancer patients,divided into the control group and the study group,36 cases in each group,the control group using 5-fluorouracil and cisplatin for treatment,the patients in study group received pemetrexed com-bined with cisplatin,comparative analysis of the clinical curative effect of the two groups.Results:after the treatment,the treatment group the total effective rate was 97.2%,significantly higher than that of the control group (P <0.05).The incidence rate of study group patients nausea and vomiting,constipation,leukope-nia,anemia and other adverse reaction were significantly lower than those in the control group (P <0.05).Conclusion:pemetrexed combined with cisplatin in treatment of advanced esophageal cancer,the curative effect,adverse reaction,patient tolerance is good,is worth the clinical promotion and application.
